BioMarin PharmaceuticalNASDAQ: BMRN

New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with Achondroplasia Phase 2 and 3 Data on VOXZOGO Demonstrate Safety, Efficacy and Impact on Proportionality and Health-Related Quality of Life for Children with Achondroplasia New Research Underscores Unmet Medical Needs of People with Hypochondroplasia SAN RAFAEL, Calif. , June 17, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increases in bone length while maintaining bone strength.

Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression Maintained Four Years Post-ROCTAVIAN Infusion Additional Data Show Meaningful Impact of ROCTAVIAN on Health-Related Quality of Life (HRQoL)  SAN RAFAEL, Calif. , June 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that new data supporting the long-term safety and efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) will be presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand, June 22-26, 2024.

The Zacks Biomedical and Genetics industry is expected to benefit from recent drug approvals and pipeline advancements, which should help sustain momentum. BMRN, BPMC, IMVT, KYMR, and LGND are well positioned with their strong portfolios and progress in their pipelines, despite market volatility.

During the ongoing earnings season, Citigroup (NYSE: C) has lowered its 12-month price targets for several companies, prompting us to analyze three stocks impacted by these cuts.

BioMarin surpassed earnings expectations in the first quarter of 2024, but fell slightly short of revenue projections. The company is still on track to meet its revenue guidance for the year.

The key metrics for BioMarin (BMRN) in the quarter ending March 2024 offer a glimpse into the company's performance, but it could be beneficial to compare these figures to Wall Street expectations and last year's results.

BioMarin Pharmaceutical (BMRN) reported quarterly earnings of $0.71 per share, surpassing the Zacks Consensus Estimate of $0.60 per share. This is an improvement from earnings of $0.60 per share in the same quarter last year.

Although many popular biotech stocks peaked in 2020 and early 2021 and then started to decline, early 2024 has seen signs of recovery and a return of investors' trust. Nonetheless, this biotech stock powered through the period, achieving miracle growth and maintaining its decades-long tradition of positive returns.

BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, it said in a filing on Monday.